Iterum Therapeutics plc Files 8-K
Ticker: ITRM · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-disclosure
Related Tickers: ITRM
TL;DR
Iterum Therapeutics filed an 8-K on 8/20/25 covering Reg FD, other events, and financials.
AI Summary
Iterum Therapeutics plc filed an 8-K on August 20, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company's principal executive offices are located at 25 North Wall Quay, Dublin 1, Ireland.
Why It Matters
This 8-K filing provides an update on Iterum Therapeutics plc's corporate activities and regulatory disclosures, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- August 20, 2025 (date) — Date of earliest event reported
- 25 North Wall Quay, Dublin 1, Ireland (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD disclosures, other events, and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 20, 2025.
Where are Iterum Therapeutics plc's principal executive offices located?
Iterum Therapeutics plc's principal executive offices are located at 25 North Wall Quay, Dublin 1, Ireland.
What is the company's telephone number?
The company's telephone number, including area code, is +353 1 6694820.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-08-20 08:15:27
Key Financial Figures
- $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
Filing Documents
- itrm-20250820.htm (8-K) — 47KB
- itrm-ex99_1.htm (EX-99.1) — 29KB
- img185001215_0.jpg (GRAPHIC) — 26KB
- 0000950170-25-110370.txt ( ) — 220KB
- itrm-20250820.xsd (EX-101.SCH) — 24KB
- itrm-20250820_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 20, 2025, Iterum Therapeutics plc (the "Company") issued a press release announcing the U.S. commercial launch of ORLYNVAH (sulopenem etzadroxil and probenecid) oral tablets for the treatment of adult women with uncomplicated urinary tract infections caused by Escherichia coli , Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information set forth in this Item 7.01 and Exhibit 99.1 attached hereto is "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.
01 Other Events
Item 8.01 Other Events. On August 20, 2025, the Company announced the U.S. commercial launch of ORLYNVAH oral tablets for the treatment of adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli , Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Iterum Therapeutics plc, dated August 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: August 20, 2025 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer